<DOC>
	<DOCNO>NCT02203916</DOCNO>
	<brief_summary>The purpose study compare antihypertensive effect azilsartan medoxomil versus placebo Korean adult essential hypertension .</brief_summary>
	<brief_title>Azilsartan Medoxomil ( TAK-491 ) Compared Placebo Korean Adults With Hypertension</brief_title>
	<detailed_description>The drug test study call azilsartan medoxomil . Azilsartan medoxomil test treat Korean adult hypertension . This study look change blood pressure people take azilsartan medoxomil . The study enroll approximately 325 patient . Participants randomly assign ( chance , like flip coin ) one three treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Azilsartan medoxomil 40 mg - Azilsartan medoxomil 80 mg - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient . All participant ask take two tablet time day throughout study . This multi-centre trial conduct Korea . The overall time participate study 12 week . Participants make 7 visit clinic , contact telephone 7 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative , sign date write informed consent form require privacy authorization prior initiation study procedure . 3 . Is treated antihypertensive therapy postwashout mean sit clinic systolic blood pressure ( SBP ) ≥150 ≤180 mm Hg Day 1 ; patient receive antihypertensive treatment within 28 day prior Screening mean sit clinic SBP ≥150 ≤180 mm Hg Screening Visit Day 1 . 4 . Is male female age ≥19 year . 5 . A female childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent 30 day last study drug dose . 6 . Is willing discontinue current antihypertensive medication Day 21 . If amlodipine chlorthalidone prior Screening , participant willing discontinue medication Day 28 . 1 . Has receive investigational compound within 30 day prior first dose study medication . 2 . Has receive TAK491 previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has sit trough clinic diastolic blood pressure ( DBP ) great 114 mm Hg Day 1 ( placebo runin ) . 5 . Has history hypersensitivity TAK491 ( azilsartan medoxomil ) , excipients , angiotensinconverting enzyme ( ARBs ) . 6 . Has history myocardial infarction , heart failure , unstable angina , coronary artery bypass graft , percutaneous coronary intervention , hypertensive encephalopathy , cerebrovascular accident , transient ischemic attack . 7 . Has clinically significant cardiac conduction defect ( e.g. , 3rd degree atrioventricular block , leave bundle branch block , sick sinus syndrome , atrial fibrillation , flutter ) . 8 . Has hemodynamically significant leave ventricular outflow obstruction due aortic valvular disease hypertrophic obstructive cardiomyopathy ( HOCM ) . 9 . Has secondary hypertension etiology ( e.g. , renovascular disease , pheochromocytoma , Cushing syndrome ) . 10 . Is noncompliant ( less 70 % great 130 % ) study medication placebo runin period . 11 . Has severe renal dysfunction disease ( confirm calculate creatinine clearance &lt; 30 mL/min/1.73m^2 ) Screening . 12 . Has know suspect unilateral bilateral renal artery stenosis . 13 . Has history drug alcohol abuse within past 2 year . 14 . Has history cancer remission least 5 year prior first dose study drug . ( This criterion apply patient basal cell stage I squamous cell carcinoma skin . ) 15 . Has type 1 poorly control type 2 diabetes mellitus ( hemoglobin A1c [ HbA1c ] &gt; 8.0 % ) Screening . 16 . Has alanine aminotransferase ( ALT ) level great 2.5 time upper limit normal , active liver disease , jaundice Screening . 17 . Has hyperkalemia ( define serum potassium great upper limit normal per central laboratory ) Screening . 18 . Has serious disease condition screen randomization would compromise participant safety , might affect life expectancy , make difficult successfully manage follow participant accord protocol . 19 . Is required take exclude medication . 20 . If female , pregnant lactate intend become pregnant , , within 30 day participate study ; intend donate ova time period .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>